Frequency Therapeutics Inc (KRRO) - Total Assets
Based on the latest financial reports, Frequency Therapeutics Inc (KRRO) holds total assets worth $161.55 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Frequency Therapeutics Inc for net asset value and shareholders' equity analysis.
Frequency Therapeutics Inc - Total Assets Trend (2017–2024)
This chart illustrates how Frequency Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Frequency Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Frequency Therapeutics Inc's total assets of $161.55 Million consist of 58.1% current assets and 41.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.6% |
| Accounts Receivable | $1.70 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Frequency Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Frequency Therapeutics Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Frequency Therapeutics Inc's current assets represent 58.1% of total assets in 2024, a decrease from 90.7% in 2017.
- Cash Position: Cash and equivalents constituted 24.6% of total assets in 2024, down from 90.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Frequency Therapeutics Inc Competitors by Total Assets
Key competitors of Frequency Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Frequency Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.71 | 11.23 | 8.45 |
| Quick Ratio | 6.71 | 11.23 | 8.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $83.59 Million | $139.17 Million | $198.43 Million |
Frequency Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Frequency Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.06 |
| Latest Market Cap to Assets Ratio | 0.46 |
| Asset Growth Rate (YoY) | 2.1% |
| Total Assets | $226.24 Million |
| Market Capitalization | $105.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Frequency Therapeutics Inc's assets below their book value (0.46x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Frequency Therapeutics Inc's assets grew by 2.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Frequency Therapeutics Inc (2017–2024)
The table below shows the annual total assets of Frequency Therapeutics Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $226.24 Million | +2.06% |
| 2023-12-31 | $221.66 Million | +200.59% |
| 2022-12-31 | $73.74 Million | -60.22% |
| 2021-12-31 | $185.36 Million | -29.98% |
| 2020-12-31 | $264.72 Million | +18.59% |
| 2019-12-31 | $223.22 Million | +401.07% |
| 2018-12-31 | $44.55 Million | +125.14% |
| 2017-12-31 | $19.79 Million | -- |
About Frequency Therapeutics Inc
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oli… Read more